The AD Dementia test is a multiparametric test that combines the detection and quantification of up to 9 metabolites or proteins in a plasma sample. The input of these measurements into an algorithm provides an accurate diagnosis and classifies the patient as either AD (Alzheimer´s disease) FTD (frontotemporal dementia), or healthy.

Biomarkers include neurotransmitters, markers of mitochondrial function, and markers of lipid metabolism dysfunction, among others.

The AD dementia test is currently in the IVD development phase, and is expected to be available as a RUO kit by 3Q of 2020.